Pfizer buys Anacor for $5.2 billion, gets access to eczema gel
Wibbitz Top Stories
2016-05-16
Views 3
Pfizer Inc will fork over $5.2 billion to buy Anacor Pharmaceuticals Inc, an eczema gel, further adding to its portfolio.
The deal comes just a month after the U.S. drug major scrapped plans to acquire Allergan Plc.Anacor shares surged more than 55 percent to $99.48 in late morning trading on Monday, above the offer price of $99.25 per share in cash.
The acquisition will givePfizer access to a non-steroidal topical gel, crisaborole, which is currently under review by the U.S. Food and Drug Administration for the treatment of mild to moderate eczema.
The deal comes just a month after the U.S. drug major scrapped plans to acquire Allergan Plc.Anacor shares surged more than 55 percent to $99.48 in late morning trading on Monday, above the offer price of $99.25 per share in cash.
The acquisition will givePfizer access to a non-steroidal topical gel, crisaborole, which is currently under review by the U.S. Food and Drug Administration for the treatment of mild to moderate eczema.
Report form
RELATED VIDEOS
